Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development

Journal of the National Cancer Institute

Volumn 98, Issue 15, 2006, Pages 1060-1067

  Young, Neville ^a   Hahn, Christopher N ^b   Poh, Alisa ^a   Dong, Carolyn ^a   Wilhelm, Dagmar ^a   Olsson, Jan ^a   Muscat, George E O ^a   Parsons, Peter ^c   Gamble, Jennifer R ^b   Koopman, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTIBODY; BROXURIDINE; CD31 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX18; UNCLASSIFIED DRUG; ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; HIGH MOBILITY GROUP PROTEIN; PROTEOGLYCAN; SOX18 PROTEIN, HUMAN; SOX18 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOSKELETON; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SOLID TUMOR; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION; UMBILICAL VEIN; WILD TYPE; ADENOVIRUS; ALLOTRANSPLANTATION; ANIMAL; BREAST TUMOR; C57BL MOUSE; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IN SITU HYBRIDIZATION; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS; ANTIGENS, CD31; BLOTTING, NORTHERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EMBRYO; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH MOBILITY GROUP PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MELANOMA; MICE; MICE, INBRED C57BL; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS; UMBILICAL VEINS; UP-REGULATION;

EID: 33747092017     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj299     Document Type: Article

References (46)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Fernando NH Hurwitz HI Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30:39-50.
3. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
6. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000;227:239-55.
7. Hosking BM, Wyeth JR, Pennisi DJ, Wang SC, Koopman P, Muscat GE. Cloning and functional analysis of the Sry-related HMG box gene, Sox 18. Gene 2001;262:239-47.
8. Pennisi DJ, James KM, Hosking B, Muscat GE, Koopman P. Structure, mapping, and expression of human SOXI8. Mamm Genome 2000; 11: 1147-9.
9. Hosking BM, Wang SC, Chen SL, Penning S, Koopman P, Muscat GE. SOX18 directly interacts with MEF2C in endothelial cells. Biochem Biophys Res Commun 2001;287:493-500.
10. Hosking BM, Wang SC, Downes M, Koopman P, Muscat GE. The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sryrelated high mobility group box gene, Sox18. J Biol Chem 2004;279:5314-22.
11. Hosking BM, Muscat GE, Koopman PA, Dowhan DH, Dunn TL. Transactivation and DNA-binding properties of the transcription factor, Sox-18. Nucleic Acids Res 1995;23:2626-8.
12. Irrthurn A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 2003;72:1470-8.
13. Green E, Mann SJ. Opossum, a semi-dominant lethal mutation affecting hair and other characteristics of mice. J Hered 1961;52:223-7.
14. Greenfield A, Dunn T, Muscat G, Koopman P. The Sry-related gene Sox18 maps to distal mouse chromosome 2. Genomics 1996;36:558-9.
15. Pennisi D, Gardner J, Chambers D, Hosking B, Peters J, Muscat G, et al. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet 2000;24:434-7.
16. James K, Hosking B, Gardner J, Muscat GE, Koopman P. Sox 18 mutations in the ragged mouse alleles ragged-like and opossum. Genesis 2003;36:1-6.
17. Permisi D, Bowles J, Nagy A, Muscat G, Koopman P. Mice null for soxl8 are viable and display a mild coat defect. Mol Cell Biol 2000;20:9331-6.
18. Fawcett SR, Klymkowsky MW Embryonic expression of Xenopus laevis SOX7. Gene Expr Patterns 2004;4:29-33.
19. Downes M, Koopman P. SOX18 and the transcriptional regulation of blood vessel development. Trends Cardiovasc Med 2001; 11:318-24.
20. Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, Kurohmaru M, et al. Depletion of definitive gut endoderm in Soxl7-null mutant mice. Development 2002;129:2367-79.
21. Saitoh T, Katoh M. Expression of human SOX18 in normal tissues and tumors. Int J Mol Med 2002;10:339-44.
22. Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med 2002;9:363-8.
23. Katoh M. Molecular cloning and characterization of human SOX17. Int J Mol Med 2002;9:153-7.
24. Teicher BAA, P.A. Anticancer Drug Development Guide, 2nd edition. Totowa (NJ): Humana Press; 1997.
25. Hahn CN, Su ZJ, Drogemuller CJ, Tsykin A, Waterman SR, Brautigan PJ, et al. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol Genomics 2005;22:57-69.
26. Jackson DE. The unfolding tale of PECAM-1. FEBS Lett 2003;540:7-14.
27. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23.
28. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-6.
29. Thernistocleous GS, Katopodis H, Sourla A, Lembessis P, Doillon CJ, Soucacos PN, et al. Three-dimensional type I collagen cell culture systems for the study of bone pathophysiology. In Vivo 2004; 18:687-96.
30. Meyer GT, Matthias LJ, Noack L, Vadas MA, Gamble JR. Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion ofvacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells. Anat Rec 1997;249:327-40.
31. Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993;121:931-43.
32. Ding L, Donate F, Parry GC, Guan X, Maher P, Levin EG. Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor. J Biol Chem 2002;277:31056-61.
33. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001;276:49289-98.
34. Banks GC, Deterding LJ, Turner KB, Archer TK Hormone-mediated dephosphorylation of specific histone H1 isoforms. J Biol Chem 2001;276:36467-73.
35. Talasz H, Helliger W, PuschendorfB, Lindner H. In vivo phosphorylation of historic H1 variants during the cell cycle. Biochemistry 1996;35:1761-7.
36. Meadows KN, Bryant P, Vincent PA, Pumigha KM. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 2004;23: 192-200.
37. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6.
38. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Hohmgren L. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54.
39. Review. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumabVEGF. Drugs R D 2002;3:28-30.
40. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93.
41. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002;5:35-44.
42. Deroanne CF, Lapiere CM, Nusgens BV. In vitro tubulogenesis of endothelial cells by relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc Res 2001;49:647-58.
43. Garcia-Ramirez M, Martinez-Gonzalez J, Juan-Babot JO, Rodriguez C, Badimon L. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vase Biol 2005;25:2398-403.
44. Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GR132 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106:3423-31.
45. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005; 11:2873-87.
46. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.